Adam is currently a Board Director at GlySens, HelpAround, Neuspera, SubjectWell, Andros, and Valera, and Board Observer to Nuvaira, Chromacode, and Upward Health. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company. Before joining I-many, Adam was a New Business Development Analyst at Cordis Corporation, a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice.
Location
New York, New York
Notable investments
No items found.
Check size range(s)
$500K - $1M
$1M - $3M
$3M - $10M
Rounds their fund invests in
Seed
Series A
Series B+
Rounds their fund leads
Seed
Series A
Series B+
Sectors their fund invests in
Health
Geographies their fund invests in
USA
Browse through a massive startup database
Browse Harmonic, our favorite resource for parsing through the world's startup data.
Partner
Learn more about Harmonic
No items found.
No colleagues here yet.
Funds they're a part of
Windham Venture Partners
About the Fund
NYC-based healthtech VC firm investing across medical technologies and digital health
View Profile
Their Colleagues
Sheets Their fund(s) are in
Is this you? Have any edits?
Fill out our update request form and we'll update ASAP
Related Investors
Round-focused Sheets
Geography-focused Sheets
Sector-focused Sheets
